635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors

• Yuan Yuan,
• Michael Klichinsky,
• Saar Gill,
• Melissa Johnson,
• Thomas Condamine,
• Jennifer Specht,
• Richard T Maziarz,
• Kim Reiss,
• Debora Barton,
• Daniel Cushing,
• Joanne Mortimer,
• Paula R Pohlmann,
• E Claire Dees,
• Naoto Ueno,
• Mathew Angelos,
• Ramona F Swaby,
• Yara Abdou

Affiliations

Yuan Yuan

8Cedars-Sinai, Los Angeles, CA, USA

Michael Klichinsky

Carisma Therapeutics, Philadelphia, PA, USA

Saar Gill

Aff125 grid.25879.310000000419368972Center for Cellular ImmunotherapiesUniversity of Pennsylvania Philadelphia PA USA

Melissa Johnson

4Sarah Cannon Research Institute, Nashville, TN, USA

Thomas Condamine

3Carisma Therapeutics, Philadelphia, PA, USA

Jennifer Specht

2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Richard T Maziarz

BMT & Cell Therapy Program, Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA

Kim Reiss

1University of Pennsylvania, Philadelphia, PA, USA

Debora Barton

3Carisma Therapeutics, Springfield, NJ, USA

Daniel Cushing

Carisma Therapeutics, Philadelphia, PA, USA

Joanne Mortimer

2City of Hope, Duarte, CA, USA

Paula R Pohlmann

3The University of Texas MD Anderson Cancer Center, Houston, TX, USA

E Claire Dees

7University of North Carolina Lineberger Comprehensive Cancer, Chapel Hill, NC, USA

Naoto Ueno

3The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Mathew Angelos

9University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA

Ramona F Swaby

10Carisma Therapeutics, Philadelphia, PA, USA

Yara Abdou

12University of North Carolina at Chapel Hill, Durham, NC, USA